Veracyte (VCYT) Operating Income (2016 - 2025)
Veracyte (VCYT) has disclosed Operating Income for 14 consecutive years, with $37.2 million as the latest value for Q4 2025.
- Quarterly Operating Income rose 790.9% to $37.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.8 million through Dec 2025, up 257.93% year-over-year, with the annual reading at $57.8 million for FY2025, 257.93% up from the prior year.
- Operating Income hit $37.2 million in Q4 2025 for Veracyte, up from $22.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $37.2 million in Q4 2025 to a low of -$45.4 million in Q1 2021.
- Historically, Operating Income has averaged -$6.7 million across 5 years, with a median of -$7.8 million in 2021.
- Biggest five-year swings in Operating Income: crashed 555.11% in 2023 and later surged 790.9% in 2025.
- Year by year, Operating Income stood at -$12.3 million in 2021, then skyrocketed by 56.05% to -$5.4 million in 2022, then plummeted by 555.11% to -$35.5 million in 2023, then soared by 111.76% to $4.2 million in 2024, then soared by 790.9% to $37.2 million in 2025.
- Business Quant data shows Operating Income for VCYT at $37.2 million in Q4 2025, $22.9 million in Q3 2025, and -$5.3 million in Q2 2025.